Zhu Cuiming

Prof. Dr. Zhu Cuiming


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
TDTingfeng Du
Tingfeng Du
ALAihua Lei
Aihua Lei
NZNaiyu Zhang
Naiyu Zhang
ZCZhu Cuiming
Zhu Cuiming
Respiratory diseases cause a high incidence and mortality worldwide. As a natural immunobiotic, Lactobacillus has excellent immunomodulatory ability. Administration of some Lactobacillus species can alleviate the symptoms of respiratory diseases such as respiratory tract infections, asthma, lung cancer and cystic fibrosis in animal studies and clinical trials. The beneficial effect of Lactobacillus on the respiratory tract is strain dependent. Moreover, the efficacy of Lactobacillus may be affected by many factors, such as bacteria dose, timing and host background. Here, we summarized the beneficial effect of administered Lactobacillus on common respiratory diseases with a focus on the mechanism and safety of Lactobacillus in regulating respiratory immunity.

1 November 2020 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
SLShuihong Li
Shuihong Li
XWXiaodan Wei
Xiaodan Wei
SLSisi Li
Sisi Li
ZCZhu Cuiming
Zhu Cuiming
CWChunhui Wu
Chunhui Wu
In the past few years, we have witnessed great development and application potential of various up-conversion luminescent nanoparticles (UCNPs) in the nanomedicine field. Based on the unique luminescent mechanism of UCNPs and the distinguishable features of cancer biomarkers and the microenvironment, an increasing number of smart UCNPs nanoprobes have been designed and widely applied to molecular imaging, cancer diagnosis, and treatment. Considerable technological success has been achieved, but the main obstacles to oncology nanomedicine is becoming an incomplete understanding of nano–bio interactions, the challenges regarding chemistry manufacturing and controls required for clinical translation and so on. This review highlights the progress of the design principles, synthesis and surface functionalization preparation, underlying applications and challenges of UCNPs-based probes for cancer bioimaging, diagnosis and treatment that capitalize on our growing understanding of tumor biology and smart nano-devices for accelerating the commercialization of UCNPs.

2 February 2023 in Journal of Applied Microbiology
Verified
Journal Article
Closed access
PDF file
NZNaiyu Zhang
Naiyu Zhang
WZWuwei Zeng
Wuwei Zeng
TDTingfeng Du
Tingfeng Du
HWHongjiang Wei
Hongjiang Wei
WTWei Tian
Wei Tian
ZCZhu Cuiming
Zhu Cuiming
To evaluate the protective effect of intestinal supplementation with Lacticaseibacillus casei CNRZ1874 on the inflammatory response induced by Mycoplasma pneumoniae in C57BL/6J mice, and provide a potential strategy for alleviating M.pneumoniae pneumonia. C57BL/6J mice were gavaged with L. casei CNRZ1874 or PBS for 7 consecutive days, and then infected with M.pneumoniae on day 8. Treatment with L. casei CNRZ1874 significantly reduced M.pneumoniae loads in the lungs and alleviated the lung inflammation on day 3 and day 10 after pathogen infection. Importantly, oral administration with L. casei CNRZ1874 promoted M1 alveolar macrophages activation as evidenced by increased expression of iNOS, TNF-α and CXCL1, while inhibited M2 alveolar macrophages activation as the expression of Arg1 and Chi3l3 were significantly decreased. In consistent with the M1 alveolar macrophages activation and enhanced mycoplasma clearance, the level of TNF-α was increased while the level of IL-4 was decreased in lung tissue from the L. casei CNRZ1874 group compared with the control group. However, oral administration with L. casei CNRZ1874 may not influence adaptive immunity induced by M.pneumoniae as evaluated by M.pneumoniae specific antibodies and T cells responses in spleen. Intestinal supplementation with L. casei CNRZ1874 can promote M1 alveolar macrophages activation, which contributes to the clearance of M. pneumoniae and attenuation of M.pneumoniae pneumonia.

5 August 2024 in Probiotics and Antimicrobial Proteins
Verified
Journal Article
Closed access
PDF file
GHGuiting He
Guiting He
HLHuanbing Long
Huanbing Long
JHJiarong He
Jiarong He
ZCZhu Cuiming
Zhu Cuiming

25 October 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HLHuanbing Long
Huanbing Long
GHGuiting He
Guiting He
JHJiarong He
Jiarong He
TDTing Feng Du
Ting Feng Du
PFPengxiao Feng
Pengxiao Feng
ZCZhu Cuiming
Zhu Cuiming
Mycoplasma pneumoniae represents one of the significant etiologies of community-acquired pneumonia in pediatric patients. However, clinical treatment of M. pneumoniae infection in children has encountered challenges due to the escalating resistance to quinolones. Numerous studies have highlighted the potential of probiotic lactobacillus administration in boosting immune responses to bacterial and viral respiratory infections. In this study, the protective efficacy of pre-oral administration of Lacticaseibacillus rhamnosus GG (LGG), Limosilactobacillus reuteri F275, Lactiplantibacillus plantarum NCIMB 8826, L. plantarum S1 or L. plantarum S2 was evaluated in the BALB/c mice model; it was observed that among these five strains of lactobacillus, the supplementation of LGG exhibited the most significant protective effect against M. pneumoniae infection. Moreover, when administered orally, both live LGG and heat-inactivated LGG have demonstrated efficacy in reducing the burden of M. pneumoniae in the lungs and alleviating pulmonary inflammation. Oral supplementation with LGG resulted in the inhibition of neutrophil recruitment into the lungs and increased recruitment of alveolar macrophages in M. pneumoniae-infected mice. Additionally, LGG supplementation led to increased production of IL-10 and secretory IgA (sIgA), while suppressing the levels of IL-1β, IL-6, IL-17A, and TNF-α in the lungs of mice infected with M. pneumoniae. The data suggests that supplementation with LGG can modulate immune responses, decrease pathogen load, and alleviate inflammatory injury in the lungs of M. pneumoniae-infected mice.

2 July 2025 in Vaccine
Verified
Journal Article
Closed access
LYLan Yu
Lan Yu
CCChunyan Chen
Chunyan Chen
GHGuiting He
Guiting He
YMYan Meng
Yan Meng
HLHuanbing Long
Huanbing Long
ZCZhu Cuiming
Zhu Cuiming